Guerbet Liver Fibrosis

ID#: NCT06703450

Age: 18 - 89 years

Gender: All

Healthy Subjects: Accepts Healthy Volunteers

Recruitment Status: Enrolling by invitation

Start Date: February 28, 2024

End Date: February 28, 2026

Summary: The goal of this study is to assess the value of liver dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and texture analysis post gadopiclenol for liver fibrosis staging, in comparison with MR elastography, T1 mapping, ultrasound elastography and blood tests in 50 initial patients with metabolic dysfunction-associated steatohepatitis (MASH).
Eligibility:

Inclusion Criteria:

- Patients with suspected MASLD (F0-F4) with clinically indicated percutaneous or transjugular liver biopsy within 6 months of MRI (before or after MRI).

- Both genders.

- Age > 18 years.

- Any racial/ethnic background.

Exclusion criteria:

- Previous history or current diagnosis of HCC or decompensation.

- Contraindications for MRI, including

- Medically unstable

- Intracranial clips

- Metal implants

- Suspected or confirmed metal in eyes

- Cardiac pacemaker, implanted defibrillator, other implanted electronic device

- Pregnancy: Pregnancy tests will be offered to women of childbearing age at no cost

- Severe claustrophobia
Find a Clinical Trial Find Cancer Clinical Trials